World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
141
Citations
131989
World Ranking
1582
National Ranking
925

Research.com Recognitions

  • 2007 - Canada Gairdner International Award
  • 2006 - Warren Alpert Foundation Prize For their contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.

Overview

Dennis J. Slamon is affiliated with the University of California, Los Angeles in the United States. Their research spans multiple areas within medicine, particularly focusing on oncology and molecular biology with significant contributions in breast cancer treatment. The scientist's main fields of study include Medicine and Biochemistry, Genetics and Molecular Biology. Their subfields of focus are Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Genetics.

The research topics associated with Dennis J. Slamon concentrate on:

  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer-related Molecular Pathways
  • Cancer Treatment and Pharmacology
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics

The scientist has published extensively in several academic journals, frequently contributing to:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)

Among their recent publications are:

  • Ribociclib plus Endocrine Therapy in Early Breast Cancer, 2024, New England Journal of Medicine
  • Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival, 2021, Annals of Oncology
  • Cycling cancer persister cells arise from lineages with distinct programs, 2021, Nature
  • Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials, 2021, The Lancet Oncology

Frequent co-authors collaborating with Dennis J. Slamon include:

  • Sara A. Hurvitz
  • Neil A. O'Brien
  • Martina S.J. McDermott
  • Michael F. Press
  • Sherene Loi

The scientist's work has been recognized with the following awards:

  • Canada Gairdner International Award, 2007
  • Warren Alpert Foundation Prize, 2006, for contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors

Best Publications

  • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

    Dennis J. Slamon;Gary M. Clark;Steven G. Wong;Wendy J. Levin

  • Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

    Dennis J. Slamon;Brian Leyland-Jones;Steven Shak;Hank Fuchs

  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

    Dennis J. Slamon;William Godolphin;Lovell A. Jones;John A. Holt

  • Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

    Charles L. Vogel;Melody A. Cobleigh;Debu Tripathy;John C. Gutheil

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • Expression of a multidrug-resistance gene in human tumors and tissues

    A T Fojo;K Ueda;D J Slamon;D G Poplack

  • Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

    Katherine B. Chiappinelli;Pamela L. Strissel;Alexis Desrichard;Huili Li

  • Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro

  • Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

    Mark D. Pegram;Allen Lipton;Daniel F. Hayes;Barbara L. Weber

  • A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers

    James R. Bischoff;Lee Anderson;Yingfang Zhu;Kevin Mossie

  • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

    Richard S Finn;John P Crown;Istvan Lang;Katalin Boer

  • Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

    Siân Jones;Tian Li Wang;Ie Ming Shih;Tsui Lien Mao

  • PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

    Richard S Finn;Judy Dering;Dylan Conklin;Ondrej Kalous

  • Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

    Gottfried E. Konecny;Mark D. Pegram;Natarajan Venkatesan;Richard Finn

  • Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

    Rashmi K Murthy;Sherene Loi;Alicia Okines;Elisavet Paplomata

  • Expression of cellular oncogenes in human malignancies

    Dennis J. Slamon;Jean B. deKernion;Inder M. Verma;Martin J. Cline

  • Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

    Nicholas C Turner;Dennis J Slamon;Jungsil Ro;Igor Bondarenko

  • Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry

    Giovanni Pauletti;Suganda Dandekar;HongMei Rong;Lilllian Ramos

  • HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

    Michael F. Press;Leslie Bernstein;Patricia A. Thomas;Lorraine F. Meisner

Frequent Co-Authors

Michael F. Press
Michael F. Press University of Southern California
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center
Beth Y. Karlan
Beth Y. Karlan University of California, Los Angeles
John Crown
John Crown Dublin City University
He-Jing Wang
He-Jing Wang University of California, Los Angeles
Marc Buyse
Marc Buyse Hasselt University
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Joan S. Brugge
Joan S. Brugge Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The healthcare landscape in the USA is changing rapidly, and online degrees are an increasingly popular way to advance or pivot within the field of medicine. For those seeking advanced practice or academic roles, online nursing doctoral programs offer flexibility and affordability, making a terminal degree more accessible for working nurses.

Looking to build on your current credentials? Explore the cheapest rn to bsn online programs, which are designed for registered nurses wanting to expand their career options with a bachelor’s degree. These cost-effective pathways can be completed while balancing work or family commitments.

If you hold a non-nursing bachelor’s degree but want to enter the nursing profession, consider direct entry msn programs for non-nursing majors online. These programs offer accelerated routes to become a registered nurse and earn a master’s degree, even with no prior nursing experience.

For those beginning their nursing journey, adn programs represent a flexible and accessible starting point. This pathway is ideal for those who want to quickly enter the workforce while keeping future advancement options open.

Best Scientists Citing Dennis J. Slamon

Trending Scientists

Recently Published Articles